SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):367P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Putzer, D.
Right arrow Articles by Virgolini, I.
PubMed
Right arrow Articles by Putzer, D.
Right arrow Articles by Virgolini, I.

Oncology-Clinical Diagnosis: Solid Tumors

Clinical Diagnosis-Solid Tumors Posters

Results of 18F-FDG PET/CT and 68Ga-DOTA-TOC PET/CT correlate with tissue markers of poor prognosis in neuroendocrine tumors

Daniel Putzer1, Dorota Kendler1, Paul Rhomberg2, Michael Gabriel1, Alexander Kroiss1, Christian Uprimny1, Boris Warwitz1, Clemens Decristoforo1 and Irene Virgolini1

1 Nuclear Medicine; 2 Radiology, Innsbruck Med U, Innsbruck, Tirol, Austria


Formula

1549

Objectives: 18F-FDG and 68Ga-DOTA-Tyr3-octreotide PET are imaging modalities used for the initial diagnosis and therapeutic assessment in neuroendocrine tumors (NET). We investigated whether the tracer uptake in these imaging modalities is affected by cellular characteristics and clinical behaviour of NET.

Methods: Sixteen patients (61±13 years, 8 male, 8 female) underwent 18F-FDG and 68Ga-DOTA-Tyr3-octreotide PET fused with CT for initial staging of NET. PET scans were acquired 60-80 minutes after i.v.-application of 370 MBq of 18F-FDG or 150 MBq 68Ga-DOTA-Tyr3-octreotide. The relationship between tracer uptake in both PET modalities and ki-67 as proliferation marker was investigated.

Results: Tracer uptake in 18F-FDG and 68Ga-DOTA-Tyr3-octreotide PET showed an association with ki-67 index cell percentage, permitting early diagnosis of highly proliferant NET with poor prognosis. In 10 patients, 18F-FDG PET showed no pathological uptake or only partial uptake in one singular lesion, while 68Ga-DOTA-Tyr3-octreotide PET was positive for high tracer uptake of all known tumor lesions. These patients had ki-67 values of 5% or lower. In 6 patients, 18F-FDG PET revealed tracer uptake in multiple tumor lesions with missing or low 68Ga-DOTA-Tyr3-octreotide uptake, associated with ki-67 index of more than 5 up to 20.

Conclusions: Ki-67 is an indicator of aggressive tumor growth and correlates very well with tracer uptake in FDG and 68Ga-DOTA-Tyr3-octreotide PET, permitting early diagnosis of highly proliferant NET with poor prognosis. FDG uptake is a prognostic and predictive factor in NET staging, associated with clinicopathological parameters that indicate a low therapy response and poor prognosis.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Putzer, D.
Right arrow Articles by Virgolini, I.
PubMed
Right arrow Articles by Putzer, D.
Right arrow Articles by Virgolini, I.